1. Home
  2. VOR vs BIOA Comparison

VOR vs BIOA Comparison

Compare VOR & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vor Biopharma Inc.

VOR

Vor Biopharma Inc.

HOLD

Current Price

$15.50

Market Cap

755.7M

Sector

Health Care

ML Signal

HOLD

Logo BioAge Labs Inc.

BIOA

BioAge Labs Inc.

HOLD

Current Price

$16.20

Market Cap

776.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VOR
BIOA
Founded
2015
2015
Country
United States
United States
Employees
168
62
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
755.7M
776.6M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
VOR
BIOA
Price
$15.50
$16.20
Analyst Decision
Buy
Strong Buy
Analyst Count
10
6
Target Price
$45.44
$51.50
AVG Volume (30 Days)
1.2M
456.5K
Earning Date
05-13-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$846.41
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.13
$3.62
52 Week High
$49.95
$24.00

Technical Indicators

Market Signals
Indicator
VOR
BIOA
Relative Strength Index (RSI) 52.53 38.97
Support Level $11.38 $15.47
Resistance Level $16.88 $22.17
Average True Range (ATR) 1.63 1.26
MACD 0.11 -0.01
Stochastic Oscillator 47.69 16.78

Price Performance

Historical Comparison
VOR
BIOA

About VOR Vor Biopharma Inc.

Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.

About BIOA BioAge Labs Inc.

Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.

Share on Social Networks: